NCT00207051View on ClinicalTrials.gov

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Colorectal Cancer
Interventions
DRUG

Brivanib + Cetuximab

Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks

Trial Locations (8)

20007

Georgetn Univ Lombardi Can Ctr, Washington D.C.

33010

University Of Miami Miller School Of Medicine, Miami

33612

H. Lee Moffitt Cancer Center, Tampa

48201

Karmanos Cancer Institute, Detroit

90033

Usc/Norris Comprehensive Cancer Center, Los Angeles

L8V 2C5

Local Institution, Hamilton

M5G 2M9

Local Institution, Toronto

1081 HV

Local Institution, Amsterdam

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY